Angiogenesis in pre-invasive cancers

Anticancer Research

Volumn 22, Issue 4, 2002, Pages 2061-2072

  Teo, Nee Beng ^a   Shoker, Balvinder S ^a   Martin, Lee ^a   Sloane, John P ^a   Holcombe, Christopher ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Invasion; Pre invasive cancers

Indexed keywords

ANGIOGENESIS INHIBITOR; TAMOXIFEN;

ANGIOGENESIS; CANCER INVASION; EXTRACELLULAR MATRIX; GROWTH INHIBITION; HORMONAL REGULATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); PRECANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION;

HUMANS; MICROCIRCULATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PRECANCEROUS CONDITIONS;

EID: 0036332186     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (186)

1. Macrophage production of vascular endothelial growth factor (VEGF) is differentially regulated by hypoxia and transforming growth factor beta-1
2. Tumour angiogenesis: Therapeutic implications
3. Tumour dormancy in vitro by prevention of neovascularisation
4. The role of angiogenesis in tumour growth
5. Quantitative technique for study of the anatomy and function of small blood vessels in tumours
6. Prolonged tumour dormancy by prevention of neovascularisation in the vitreous
7. Integrin alphaVbeta3 antagonists promote tumour regression by inducing apoptosis of angiogenic blood vessels
8. Inhibition of angiogenesis
9. Tumour interactions with the vasculature: Angiogenesis and tumour metastasis
10. The prognostic significance of tumour vascularity in intermediate-thickness (0.76-4mm) skin melanoma
11. Angiogenesis and colonizing in the tumour metastatic process: Basic and applied advances
12. Tumour associated angiogenesis in prostate cancer
13. Tumour microvessel density, p53 expression, tumour size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma
14. Angiogenesis and breast cancer
15. Angiogenesis in breast carcinoma-clinicopathologic relevance and potential use as a quantifiable surrogate endpoint biomarker
16. Tumour angiogenesis correlates with metastasis in invasive prostate carcinoma
17. Tumour angiogenesis: A new significant and independent prognostic indicator in early stage breast carcinoma
18. Tumour angiogenesis - Correlation in invasive breast carcinoma
19. Tumour angiogenesis in human lung, adenocarcinoma
20. Intratumoral micro-vessels density and p53 protein correlation with metastasis in head and neck squamous cell carcinoma
21. Extent of vascularisation as a prognostic indicator in thin (<0.76mm) malignant melanomas
22. Initial stages of tumour-cell induced angiogenesis: Evalution via skin window chambers in rodent models
23. Tumour angiogenesis and the role of vascular cell integrin alphaVbeta3
24. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops
25. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis
26. Tumour angiogenesis and tissue factor
27. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity
28. Angiogenesis inhibitors generated by tumours
29. Angiogenesis in cancer, vascular, rheumatoid and other disease
30. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
31. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
32. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype
33. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ
34. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumour angiogenesis
35. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells
36. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels
37. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression
38. Oncogenic H-ras stimulates tumour angiogenesis by two distinct pathways
39. The angiogenic switch in hamster buccal pouch keratinocytes is dependent on TGFbeta-1 and is unaffected by ras activation
40. Comparison of VEGF, VEGF-B, VEGF-C and Ang-I mRNA regulation by serum, growth factors, oncoproteins and hypoxia
41. VEGF mRNA is stabilized by ras and tyrosine kinase oncogenes, as well as by UV radiation - Evidence for divergent stabilization pathways
42. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression I melanoma, lung and breast carcinoma cell lines
43. Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells
44. Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down- regulate VEGF production by tumour cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumours
45. Reciprocal paracrine interactions between tumour cells and endothelial cells: The "angiogenesis progression" hypothesis
46. Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during diseased progression
47. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: Role of infiltrating cells
48. Macrophages and angiogenesis
49. Elevated vascular endothelial growth factor M breast cancer: A proposed mechanism
50. Oxygen tension regulates the expression of angiogenesis factor by macrophages
51. Macrophages and their putative significance in human breast cancer
52. Activated macro-phages induce vascular proliferation
53. P53 and angiogenesis
54. Diversity of function is inherent in matrix proteins: An appraisal of thrombospondin-1
55. Macrophages and angiogenesis
56. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma
57. Macrophages-induced angiogenesis: A review
58. Tumour-associated macrophages in neoplastic progression: A paradigm for the in vivo function of chemokines
59. Tumour-elicited polymorphonuclear cells, in contrast to 'normal' circulating polymorphonucleaar cells, stimulate invasive and metastatic potentials of rat mammary adenocarcinoma cells
60. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma
61. Relationship between matrix metalloproteinase expression and tumour angiogenesis in human breast carcinoma
62. Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer
63. Angiogenesis and inflammation in ductal carcinoma in situ of the breast
64. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis
65. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer
66. A highly conserved vascular permeability factor secreted by variety of human and rodent tumour cell lines
67. The role of vascular endothelial growth factor in pathological angiogenesis
68. Tumour angiogenesis: The pivotal role of vascular endothelial growth factor
69. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
70. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor
71. Growth factors in angiogenesis: Current interest and therapeutic potential
72. Vascular endothelial growth factor is induced in response to transforming growth factor beta in fibroblastic and epithelial cells
73. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression
74. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells
75. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
76. Hypoxia regulatory elements of the human vascular endothelial growth factor gene
77. Transcription regulation of the rat vascular endothelial growth factor gene by hypoxia
78. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts
79. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression
80. Vascular permeability factor/vascular endothelial growth factor, microvascular hypermeability, and angiogenesis
81. Molecular framework for angiogenesis: A complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines
82. Expression of the angiogenic factors vascular endothelial growth factor, acidic and basic fibroblast factor, tumour growth factor beta 1, platelet-derived endothelial growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
83. Angiogenesis factors
84. Site-directed neovessel formation in vivo
85. The fibroblast growth factor family: Structural and biological properties
86. Structure and activities of acidic fibroblast growth factor
87. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth
88. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo
89. Neovascularisation is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma
90. Effects of modulation of basic fibroblast growth factor on tumour growth in vivo
91. Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane
92. Suppression of solid tumour growth by immuno-neutralizing monoclonal antibody against human basic fibroblast growth factor
93. Angiogenic factor
94. Purification and properties of an endothelial cell growth factor from human platelets
95. Production of plate let-derived endothelial cell growth factor by normal and transformed human cells in culture
96. Platelet-derived growth factor is angiogenic in vivo
97. Regulators of angiogenesis
98. Transforming growth factor beta1 is implicated in the failure of tamoxifen therapy in human breast cancer
99. Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
100. Some recent advances in the chemistry and biology of transforming growth factor beta
101. Neutralisation of TGF betal and TGF beta2 or exogenous addition of TGF beta3 to cutaneous rat wounds reduces scarring
102. Platelet-derived growth factor (BB homodimer), transforming growth factor beta1, and basic fibroblast growth factor in dermal wound healing. Neovessel and matrix formation and cessation of repair
103. Biphasic effects of transforming growth factor beta1 on in vitro angiogenesis
104. Secretion of epidermal growth factor by macrophages associated with breast carcinoma
105. Integrins: Structure, function and biological properties
106. Integrins: Versatility, modulation and signaling in cell adhesion
107. Cell adhesion induces the expression of growth-associated genes in suspension-arrested fibroblasts
108. A link between cyclin A expression and adhesion-dependent cell cycle proliferation
109. Integrin alpha5beta1 expression negatively regulates cell growth: Reversal by attachment to fibronectin
110. The extracellular matrix as a cell survival factor
111. Integrin alpha5beta3 rescues melanoma cells from apoptosis in a three dimensional dermal collagen
112. Requirement of vascular integrin alpha5beta3 for angiogenesis
113. A tumour suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin
114. Approaches to studying cell adhesion molecules in angiogenesis
115. A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis
116. Human endothelial cells synthesize and express an Arg-Gly-Asp directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor
117. Requirement of integrin beta3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen
118. Confocal microscopic analysis of integrin expression on the microvasculature and its sprouts in the neonatal foreskin
119. Basic fibroblast growth factor increases expression of the alpha5beta3 complex on human microvessel endothelial cells
120. Transcient functional expression of alphaVbeta3 on vascular cells during wound repair
121. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression
122. Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast
123. Hypoxia induces a human macrophage cell line to release tumour necrosis factor-alpha and its soluble receptors in vitro
124. Tumour necrosis factor induction of urokinase-type plasminogen activator in human endothelial cells
125. Dual role of tumour necrosis factor-alpha in angiogenesis
126. Cytokine networks in solid human tumours: Regulation of angiogenesis
127. Inhibition of interleukin-8 attenuates angliogenesis in bronchogenic carcinoma
128. Interleukin-8: A corneal factor that induces neovascularization
129. Endotoxin is angiogenic
130. Role of endotoxin in mononuclear phagocyte-mediated inflammatory responses
131. Sustained release endotoxin. A model for inducing corneal neovascularisation
132. Thrombospondin: Synthesis and secretion by cells in culture
133. Molecular mechanisms of blood vessel formation
134. Angiogenesis
135. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene
136. Tumour angiogenesis: The role of oncogenes and tumour suppressor genes
137. Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysaccharide
138. Transfection of thrombospondin 1 complementary DNA into a human breast cancer cell line reduces primary tumour growth, metastatic potential and angiogenesis
139. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
140. Angiostatin induces and sustains dormancy of human primary tumour in mice
141. Endostatin: An endogenous inhibitor of angiogenesis and tumour growth
142. VEGF/VPF over-expression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumour development
143. Angiogenic capacity of preneoplastic lesions of the murine mammary gland as a marker of neoplastic transformation
144. Angiogenesis: A marker for neoplastic transformation of mammary papillary hyperplasia
145. Acquisition of angiogenic capacity and neoplastic transformation in the rat mammary gland
146. Angiogenic responsed elicited from chorioallantoic membrane vessels by neoplastic, preneoplastic, and normal mammary tissues from GR mice
147. Angiogenic potential of malignant and non-malignant human breast tissues in an in vivo angiogenesis model
148. Angiogenesis and risk of breast cancer in women with fibrocyctic disease
149. Neovascularisation in hyperplastic, metaplastic and potentially preneoplastic lesions of the bronchial mucosa
150. Modulation of neoangiogenesis in bronchial preneoplastic lesions
151. Induction of angiogenesis during the transition from hyperplasia to neoplasia
152. Arterial elements and perisinusoidal cells in borderline hepatocellular nodules and small hepatocellular carcinomas
153. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression
154. Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder
155. Angogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia
156. Demonstration and characterization of the angiogenic properties of cervical dysplasia
157. Angiogenesis in cervical neoplasia: Microvessel quantitation in precancerous lesions and invasive carcinomas with clinicopathological correlations
158. Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice
159. Transforming growth factor alpha
160. Transforming growth factor alpha in epithelial proliferative disease of the breast
161. Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast
162. Ten-year results comparing mastectomy to excision and raditation therapy for ductal carcinoma in situ of the breast
163. Prognostic classification of breast ductal carcinoma in situ
164. A prognostic index for ductal carcinoma in situ of the breast
165. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment
166. Salvage treatment for local recurrence following breast conserving surgery and definitive irradiation for ductal carcinoma in situ (intraductal carcinoma) of the breast
167. Fifteen-year results of breast-conserving srugery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast
168. Microvessel density and distribution in ductal carcinoma insitu of the breast
169. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast
170. Up-regulation of Thymidine Phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast
171. Comparative morphometric evaluation of microvessel density and nuclear area in ductal carcinoma in-situ and hyperplastic ductal breast lesions
172. Angiogenesis and expression of Thymidine Phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast
173. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
174. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer
175. Vascular permeability factor (Vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast
176. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model
177. Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis
178. Inhibition of angiogenesis by anti-estrogens
179. Antiestrogens inhibit endothelial cell growth
180. Tamoxifen is anti-angiogenic in vitro and attenuates VEGF-mediated angiogensis in vivo without adverse effects on wound healing
181. Inhibition of vascular endothelial growth factor-induced anglogenesis suppresses tumour growth in vivo
182. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer
183. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
184. Ductal carcinoma in situ: MR imaging histopathologic correlation
185. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
186. Tamoxifen for early breast cancer: An overview of the randomised trials